NovaSight announced the publication of the study “High-adherence dichoptic treatment versus patching in anisometropic and small angle strabismus amblyopia: a randomized controlled trial” in the American Journal of Ophthalmology. The study demonstrated that amblyopia patients who adhered to the CureSight treatment protocol — using the company’s novel binocular eye-tracking device — achieved greater improvements in visual acuity (VA) than those undergoing traditional occlusion therapy, or patching, in a multi-center randomized controlled trial.

The study included 149 children with amblyopia who were randomized to either CureSight digitized binocular treatment or patching. Results from the per protocol (PP) dataset of the trial (n=54) demonstrated that CureSight was more effective than patching with greater VA improvements and higher adherence rates compared to those undergoing patching (n=56). The mean improvement in distance VA in the PP CureSight group at the conclusion of a 16-week treatment was 2.8 lines, which was 0.53 lines higher than what was achieved in the patching group. Median adherence in the modified intent-to-treat CureSight group was 94%, which was also higher than in the patching group, at 83.9%.